Gebruikersprofielen voor "Kremer, J. "

Jan Kremer

Professon in patientcentered innovation
Geverifieerd e-mailadres voor radboudumc.nl
Geciteerd door 15589

[PDF][PDF] 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the …

JA Singh, DE Furst, A Bharat, JR Curtis… - Arthritis care & …, 2012 - Wiley Online Library
The American College of Rheumatology (ACR) most recently published recommendations
for the use of diseasemodifying antirheumatic drugs (DMARDs) and biologic agents in the …

Women's emotional adjustment to IVF: a systematic review of 25 years of research

CM Verhaak, JMJ Smeenk, AWM Evers… - Human reproduction …, 2007 - academic.oup.com
This review provides an overview of how women adjust emotionally to the various phases of
IVF treatment in terms of anxiety, depression or general distress before, during and after …

Physical exercise and psychological well being: a critical review.

D Scully, J Kremer, MM Meade, R Graham… - British journal of sports …, 1998 - bjsm.bmj.com
The relation between physical exercise and psychological health has increasingly come
under the spotlight over recent years. While the message emanating from physiological …

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: results of a twenty‐four …

S Cohen, E Hurd, J Cush, M Schiff… - Arthritis & …, 2002 - Wiley Online Library
Objective To evaluate the efficacy and safety of anakinra in combination with methotrexate (MTX)
in patients with active rheumatoid arthritis (RA). Methods Patients with moderate‐to‐…

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results …

P Emery, E Keystone, HP Tony, A Cantagrel… - Annals of the …, 2008 - ard.bmj.com
Objectives: The phase III RADIATE study examined the efficacy and safety of tocilizumab, an
anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory …

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve‐month results of a phase IIb, double‐blind, randomized, placebo …

JM Kremer, M Dougados, P Emery… - … : Official Journal of …, 2005 - Wiley Online Library
Objective To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA‐4Ig),
a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has …

2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis

L Fraenkel, JM Bathon, BR England… - Arthritis & …, 2021 - Wiley Online Library
Objective To develop updated guidelines for the pharmacologic management of rheumatoid
arthritis. Methods We developed clinically relevant population, intervention, comparator, …

Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double‐blind, placebo‐controlled trial

EC Keystone, MH Schiff, JM Kremer… - … : Official Journal of …, 2004 - Wiley Online Library
Objective To evaluate the safety, efficacy, and pharmacokinetics of 50 mg etanercept
administered subcutaneously once weekly in adult patients with active rheumatoid arthritis (RA). …

Computer visualization of three-dimensional image data using IMOD

JR Kremer, DN Mastronarde, JR McIntosh - Journal of structural biology, 1996 - Elsevier
We have developed a computer software package, IMOD, as a tool for analyzing and viewing
three-dimensional biological image data. IMOD is useful for studying and modeling data …

[HTML][HTML] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition

MC Genovese, JC Becker, M Schiff… - … England Journal of …, 2005 - Mass Medical Soc
Background A substantial number of patients with rheumatoid arthritis have an inadequate
or unsustained response to tumor necrosis factor α (TNF-α) inhibitors. We conducted a …